Potassium 用于心律失常

C 证据来自小型研究的证据有限，但存在一些积极信号。

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

𝕏 LinkedIn

<\/script>\n

`; }, get iframeSnippet() { const domain = 'heartcited.com'; const params = 'ingredient\u003Dpotassium\u0026condition\u003Darrhythmia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style

Widget powered by . Free, no account required.

结论

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

Key Study Findings

Other n=19 1 weeks

Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study.

Dose: 50 mg vs: baseline Outcome: cardiac repolarisation 效果: None p=0.07

研究人群: lqts with a disease-causing kcnq1 or kcnh2 variant

Cohort Study n=157766 26.0 weeks

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a …

Dose: None vs: None Outcome: Incidence of hyperkalemia, mortality 效果: None None

研究人群: Newly diagnosed CKD patients in Denmark

Observational Study n=40

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1).

Dose: anti-digoxin antibodies (Fab) vs: pre-treatment Outcome: serum digoxin and clinical outcomes 效果: Fab bound digoxin; no improved clinical outcomes None

研究人群: Chronic digoxin toxicity patients

Other

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, …

Dose: None vs: None Outcome: None 效果: None None

研究人群: None

Other

Potassium supplements or potassium-sparing agents.

Dose: None vs: None Outcome: mineral status 效果: None None

研究人群: hypertensive patients

Key Statistics

研究数量

300

受试者

↑

Positive

等级

Referenced Papers

Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study. Other

Open heart 2021 6 次引用

Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. Other

Nephrology, dialysis, transplantation … 2018 83 次引用

Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). Observational

Clinical toxicology (Philadelphia, … 2016 25 次引用

Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common … Other

Therapeutic drug monitoring 2011 17 次引用

Potassium supplements or potassium-sparing agents. Other

Acta pharmacologica et … 1984 3 次引用

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

常用剂量

supplements:: Typically 99 mg/dose (FDA limit per unit)
dashdiettarget:: 4,700 mg/day
whorecommendation:: 3,510 mg/day from food

上限： No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

研究中使用的剂量

剂量	持续时间	效果	N
50 mg	1 weeks	Neutral	19
None	26.0 weeks	Mixed	157766
anti-digoxin antibodies (Fab)	--	Neutral	40
None	--	Positive	--
None	--	Mixed	--

最佳服用时间： With meals to reduce GI irritation; divide supplemental doses throughout the day

Safety & Side Effects

已报告的副作用

⚠ Gastrointestinal irritation (nausea, vomiting, diarrhea)
⚠ Hyperkalemia risk in patients with renal impairment
⚠ Cardiac arrhythmias at excessively high serum levels

已知相互作用

● ACE inhibitors (increased hyperkalemia risk)
● ARBs (increased hyperkalemia risk)
● Potassium-sparing diuretics (increased hyperkalemia risk)
● NSAIDs (may increase potassium retention)

可耐受最高摄入量： No UL for dietary potassium in healthy individuals; supplemental potassium should be supervised

在开始服用任何补充剂之前，请务必咨询您的医疗保健提供者。

Frequently Asked Questions

Does Potassium help with 心律失常?

Based on 5 studies with 300 participants, there is limited but promising evidence that Potassium may support 心律失常 management. Our evidence grade is C (Some Evidence).

How much Potassium should I take for 心律失常?

Studies have used various dosages. A commonly studied range is Typically 99 mg/dose (FDA limit per unit). Always consult your healthcare provider before starting any supplement regimen.

Are there side effects of Potassium?

Reported side effects may include Gastrointestinal irritation (nausea, vomiting, diarrhea), Hyperkalemia risk in patients with renal impairment, Cardiac arrhythmias at excessively high serum levels. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.

How strong is the evidence for Potassium and 心律失常?

We rate the evidence as Grade C (Some Evidence). This rating is based on 5 peer-reviewed studies with 300 total participants. The overall direction of effect is positive.

其他成分用于心律失常

Omega-3 Fatty Acids (EPA/DHA) B Magnesium B Coenzyme Q10 (CoQ10) C

Potassium 用于其他健康状况

高血压 B

快速结论

Hypokalemia is a well-established arrhythmia trigger. Guidelines support maintaining serum K+ >4.0 mEq/L. Research on supplementation benefit in normokalemic patients is unclear.

Evidence Strength52%

Moderate confidence

研究分析

RCT (0)Meta (0)Other (5)

对比替代方案

查看其他成分针对该健康状况的对比结果。

查看所有成分用于心律失常

了解更多

References

[1] Peter Marstrand et al.. Open Heart. 2021. Effect of moderate potassium-elevating treatment in long QT syndrome: the TriQarr Potassium Study. doi:10.1136/openhrt-2021-001670 PubMed
[2] Reimar W Thomsen et al.. Nephrol Dial Transplant. 2018. Elevated potassium levels in patients with chronic kidney disease: occurrence, risk factors and clinical outcomes-a Danish population-based cohort study. doi:10.1093/ndt/gfx312 PubMed
[3] Betty S Chan et al.. Clin Toxicol (Phila). 2016. Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1). doi:10.1080/15563650.2016.1175620 PubMed
[4] Andrea DeFrance et al.. Ther Drug Monit. 2011. Abbott ARCHITECT clinical chemistry and immunoassay systems: digoxin assays are free of interferences from spironolactone, potassium canrenoate, and their common … doi:10.1097/FTD.0b013e3181fd4c30 PubMed
[5] S Persson. Acta Pharmacol Toxicol (Copenh). 1984. Potassium supplements or potassium-sparing agents. doi:10.1111/j.1600-0773.1984.tb03642.x PubMed

FDA 免责声明: 这些声明未经美国食品药品监督管理局（FDA）评估。本网站上的产品和信息无意用于诊断、治疗、治愈或预防任何疾病。所展示的证据等级基于我们对已发表的同行评审研究的分析，不构成医疗建议。在开始任何补充剂方案之前，请务必咨询您的医疗保健提供者。

Potassium 用于 心律失常

Embed This Widget

结论

Key Study Findings

Key Statistics

Referenced Papers

Dosage & Usage

常用剂量

研究中使用的剂量

Safety & Side Effects

已报告的副作用

已知相互作用

Frequently Asked Questions

Related Evidence

其他成分用于 心律失常

Potassium 用于其他健康状况

References

Potassium 用于心律失常

其他成分用于心律失常